Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Change in Inventory (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Change in Inventory for 13 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Inventory rose 250.59% to $2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.6 million, a 318.17% increase, with the full-year FY2025 number at $11.6 million, up 318.17% from a year prior.
  • Change in Inventory was $2.0 million for Q4 2025 at Niagen Bioscience, down from $4.4 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $4.4 million in Q3 2025 to a low of -$2.8 million in Q1 2023.
  • A 5-year average of $457200.0 and a median of $469000.0 in 2021 define the central range for Change in Inventory.
  • Peak YoY movement for Change in Inventory: surged 656.41% in 2023, then crashed 1613.85% in 2024.
  • Niagen Bioscience's Change in Inventory stood at $926000.0 in 2021, then tumbled by 203.56% to -$959000.0 in 2022, then surged by 298.23% to $1.9 million in 2023, then plummeted by 171.12% to -$1.4 million in 2024, then skyrocketed by 250.59% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Change in Inventory are $2.0 million (Q4 2025), $4.4 million (Q3 2025), and $3.2 million (Q2 2025).